Related to High Enzyme Levels May Indicate That Chronic Lymphocytic Leukemia Will Be Aggressive

• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• Pharma Touting Phase II/III Wins in Run-Up to ASCO
  
• Roche's Antibody Approved as Front-Line Leukemia Treatment in Europe
  
• Malfunction in Immune Response Pathway Is Key to How a Fused Gene Promotes Childhood Leukemia
  
• Genzyme Acquires MS and CLL Therapy as well as Two More Oncology Products from Bayer
  
• Sanofi-Aventis Shells Out $65M to Antisoma for U.S. Rights to Leukemia Drug
  
• Scientists Pinpoint Enzyme Involved in Resistance to Childhood Leukemia Drug
  
• Phase III Success Could Mean Label Expansion for Genzyme’s CLL Drug
  
• Genmab and GSK Achieve Accelerated FDA Clearance of CLL Drug
  
• Genzyme’s Combination Therapy for Second-Line CLL Comes up Trumps in Phase III
  
• Method Discovered to Make Leukemic Cells Vulnerable to Apoptosis
  
• FDA Grants New Approval for Rituxan in CD20-Positive CLL
  
• Researchers Identify Gene-Expression Signature that Predicts Relapse Risk in T-ALL Patients
  
• MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front
  
• Scientists Correlate RNA-Binding Protein with Leukemia Prognosis
  
• Life Technologies and UCSD Enter CLL Sequencing Research Program
  
• Scientists Claim TIF1-Gamma Levels Could Represent Biomarker of Response to Leukemia Therapy
  
• Inhibiting Cystine Transporter in Stromal Cells Cuts off Key Leukemia Lifeline
  
• Researchers Find Gene Silenced Early in the Development of Chronic Lymphocytic Leukemia
  
• Pilot Clinical Trial Shows Engineered Autologous T-Cell Therapy Eradicates CLL